Farmabios

markets a portfolio of corticosteroid APIs, with a long-standing position in adrenal-cortical and reproductive-hormone manufacturing.

Country: Italy

Commercial Corticosteroid API

Coverage

	CN	EU	US
therapeutics-platforms	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Funding	Total of over €80 million invested in Farmabios as of 2025 (including a €35 million expansion announced in 2025 and €45 million previously committed over five years)	axplora.com · bioprocessintl.com · outsourcedpharma.com
Certification	cGMP approved by AIFA; holds multiple GMP certificates for active pharmaceutical ingredients (APIs)	chemanager-online.com · extranet.who.int · manufacturingchemist.com · axplora.com · outsourcedpharma.com
Regulatory approval	cGMP approval from AIFA for large-scale HPAPI and steroid production; site inspected and considered compliant with WHO GMP guidelines	chemanager-online.com · extranet.who.int · manufacturingchemist.com · axplora.com · outsourcedpharma.com
Production site	Gropello Cairoli, Italy (Via Pavia, 1)	extranet.who.int · fatturatoazienda.it
Headcount	375 employees as of 2024	axplora.com · bioprocessintl.com · fatturatoazienda.it · outsourcedpharma.com
Revenue	127.4 million EUR for fiscal year 2024	fatturatoazienda.it

Independent sources: axplora.com · bioprocessintl.com · chemanager-online.com · extranet.who.int · fatturatoazienda.it · manufacturingchemist.com · outsourcedpharma.com

Technologies

Name	Cluster	Risk
Biosynthetic steroids (fermentation & biocatalytic API)	therapeutics-platforms	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.